NEULANDLAB · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 64/100 — Quality 81 · Valuation 10 · Growth 77 · Momentum 90
| Share price | ₹18,949.00 |
| Market cap | ₹16,471 Cr |
| P/E ratio | 91.7 |
| P/B ratio | 10.2 |
| ROE | 25.8% |
| ROCE | 20.5% |
| Dividend yield | 0.09% |
| Book value | ₹1,262.78 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,023 Cr | ₹364 Cr | 29.0% |
| 2025 | ₹1,477 Cr | ₹260 Cr | 22.0% |
| 2024 | ₹1,559 Cr | ₹300 Cr | 30.0% |
| 2023 | ₹1,191 Cr | ₹164 Cr | 23.0% |
| 2022 | ₹951 Cr | ₹64 Cr | 15.0% |
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.